Henlius

#HenliusMedicalHub📌 The 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI) will be held on January 23-25 in San Francisco, California. Stay tuned for Henlius' extensive latest results as we pave the way toward a patient-centered future for cancer treatment.💡 #Henlius #ASCOGI2025 #GastrointestinalCancers #Oncology

#HenliusMedicalHub🌟Exciting News! #Henlius is gearing up for the 43rd Annual J.P. Morgan Healthcare Conference, happening from January 13-16, 2025, in San Francisco, CA. Don't hesitate to connect with us and reach out to Ping Cao, our Chief Business Development Officer. Stay tuned for more updates! 🔭 #Healthcare #Innovation #JPM2025

#HenliusCaresForLife 🎀 2024 was a tremendous year for #Henlius, joining hands with partners throughout society to restore health and improve lives. Henlius is committed to improving patient well-being, spreading health related knowledge, and strengthening grassroots medical support in communities where we work with charitable initiatives. We believe acts that improve the welfare of others, no matter how small, are capable of burning bright and inspiring change. We hope this year our efforts have brought more health and joy to the world, and we look forward to an even more impactful 2025. 🎉 #CSR #PublicWelfare #BreastCancer #LungCancer #Healthcare

#HenliusInFocus 🌍 This year, we expanded access to our innovative biologics across North America, Europe, APAC, MENAT, and LATAM, driving progress to meet patient needs worldwide. From global trials to approvals and first shipments, we’re shaping a healthier world through innovation and access. 🌟 #HealthcareInnovation #Biopharma #Henlius #2024Highlights

#HenliusForOne 🎊 Happy New Year, with Health by Your Side! #Henlius deeply values your trust and support in 2024. As we step into 2025, our commitment to patients is stronger than ever. We will continue to innovate and provide high-quality, affordable #healthcare solutions worldwide.

#HenliusInFocus ✨ In an exclusive interview with Forbes China 福布斯中国, Dr. Jason Zhu (Jason Zhu MD MBA), Executive Director and CEO of #Henlius, shared insights into the company’s latest advancements on its globalization journey. Dr. Jason Zhu stated that Henlius is navigating the "deep waters" of #globalization 2.0 era, with a clear focus on becoming the pioneer in the global expansion of Chinese #biopharmaceutical industry. He also highlighted the importance of boldly investing in the company’s vision to scale life-saving solutions worldwide.

#HenliusMedicalHub 🌍 Henlius announces the first Chinese patient dosed in the Phase 3 MRCT (ELAINE-3, NCT05696626) of HLX78 (lasofoxifene), licensed from Sermonix Pharmaceuticals for the treatment of ER+/HER2- #breastcancer harboring ESR1 mutation. 🔬 Why this matters: - Up to 40% of patients who have received aromatase inhibition (AI) for mBC have ESR1 mutations. - Potentiality to treat patients who have acquired endocrine resistance due to ESR1 mutations. - Active ELAINE-3 enrollment already underway in the U.S., Canada, and the EU. Adhering to benefiting more patients with unmet clinical needs, #Henlius will enhance the introduction and cooperation of innovative medicine to further provide high-quality, affordable treatments globally. 🔗 Learn more: https://lnkd.in/grVnZGqC #CancerResearch #Oncology

#HenliusMedicalHub 🌟 At APA/JPS/CAP/IAP 2024, Henlius shared promising Phase 2 results of HANSIZHUANG (serplulimab) in an oral presentation, showcasing its potential for first-line treatment of metastatic pancreatic ductal adenocarcinoma. 🔑 Highlights: ✅ 6-month PFS rate: 74.48% | mPFS: 8.6 months | mOS: 15.5 months ✅ ORR: 75% | DCR: 100% These findings offer new hope for patients with one of the most challenging cancers, potentially paving the way for more effective first-line treatments. #Henlius has established a broad presence in #gastrointestinalcancers, and we remain committed to delivering innovative therapies that address unmet needs in this field. 🔗Learn more: https://lnkd.in/gb8V9wtv #Oncology #PancreaticCancer

#HenliusInFocus 🌍 We’re excited to announce that Henlius has partnered with Palleon Pharmaceuticals to develop and commercialize E-602, a first-in-class human sialidase enzyme therapeutic, in combination with our self-developed HANLIKANG (rituximab) in China. This collaboration aims to address #AutoimmuneDiseases such as #LupusNephritis. Palleon is at the forefront of glyco-immunology drug development, and we look forward to advancing these groundbreaking treatments together! 🔗Learn more: https://lnkd.in/gZk2_UqA

#HenliusInFocus 🌍 As the newest member company of the Biosimilars Forum, Henlius looks forward to more opportunities that make quality medicine more accessible and affordable. Biosimilars help expand access to affordable and advanced biologics, allowing more patients to benefit from cutting edge therapy. Join us in encouraging awareness, adoption and availability of biosimilars around the world. #Biosimilars #Healthcare #Henlius Read more: https://lnkd.in/gbm8ET5j